

Chad A Newton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/122985/publications.pdf>

Version: 2024-02-01

26
papers

1,394
citations

516710

16
h-index

610901

24
g-index

26
all docs

26
docs citations

26
times ranked

1550
citing authors

#	ARTICLE	IF	CITATIONS
1	Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive. <i>European Respiratory Journal</i> , 2016, 48, 1710-1720.	6.7	281
2	The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control study. <i>Lancet Respiratory Medicine</i> , 2017, 5, 639-647.	10.7	206
3	Whole-Exome Sequencing in Adults With Chronic Kidney Disease. <i>Annals of Internal Medicine</i> , 2018, 168, 100.	3.9	154
4	Telomere length and genetic variant associations with interstitial lung disease progression and survival. <i>European Respiratory Journal</i> , 2019, 53, 1801641.	6.7	119
5	Telomere Length and Use of Immunosuppressive Medications in Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 336-347.	5.6	99
6	Telomere length in patients with pulmonary fibrosis associated with chronic lung allograft dysfunction and post-lung transplantation survival. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 845-853.	0.6	93
7	Pulmonary fibrosis in the era of stratified medicine. <i>Thorax</i> , 2016, 71, 1154-1160.	5.6	67
8	Somatic mutations in telomerase promoter counterbalance germline loss-of-function mutations. <i>Journal of Clinical Investigation</i> , 2017, 127, 982-986.	8.2	60
9	Lung function trajectory in progressive fibrosing interstitial lung disease. <i>European Respiratory Journal</i> , 2022, 59, 2101396.	6.7	40
10	Utility of Bronchoalveolar Lavage and Transbronchial Biopsy in Patients with Hypersensitivity Pneumonitis. <i>Lung</i> , 2018, 196, 617-622.	3.3	36
11	Leukocyte telomere length and mycophenolate therapy in chronic hypersensitivity pneumonitis. <i>European Respiratory Journal</i> , 2021, 57, 2002872.	6.7	32
12	Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis. <i>Lancet Respiratory Medicine</i> , 2022, 10, 593-602.	10.7	31
13	Family History of Pulmonary Fibrosis Predicts Worse Survival in Patients With Interstitial Lung Disease. <i>Chest</i> , 2021, 159, 1913-1921.	0.8	28
14	Rare and Common Variants in <i>KIF15</i> Contribute to Genetic Risk of Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 56-69.	5.6	25
15	Myositis-specific antibodies identify a distinct interstitial pneumonia with autoimmune features phenotype. <i>European Respiratory Journal</i> , 2020, 56, 2001205.	6.7	24
16	Familial Pulmonary Fibrosis. <i>Chest</i> , 2021, 160, 1764-1773.	0.8	21
17	Clinical Genetics in Interstitial Lung Disease. <i>Frontiers in Medicine</i> , 2018, 5, 116.	2.6	19
18	The Role of Genetic Testing in Pulmonary Fibrosis. <i>Chest</i> , 2022, 162, 394-405.	0.8	19

#	ARTICLE	IF	CITATIONS
19	Role of Antigen Type in Survival in Chronic Hypersensitivity Pneumonitis. <i>Lung</i> , 2019, 197, 113-114.	3.3	12
20	Pleuroparenchymal fibroelastosis associated with telomerase reverse transcriptase mutations. <i>European Respiratory Journal</i> , 2017, 49, 1700696.	6.7	8
21	Utility of Bronchoalveolar Lavage and Transbronchial Biopsy in Patients with Interstitial Lung Disease. <i>Lung</i> , 2020, 198, 803-810.	3.3	6
22	Pirfenidone for Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 374-376.	5.6	5
23	Molecular Markers and the Promise of Precision Medicine for Interstitial Lung Disease. <i>Clinics in Chest Medicine</i> , 2021, 42, 357-364.	2.1	4
24	Interstitial Pneumonia with Autoimmune Features: What the Rheumatologist Needs to Know. <i>Current Rheumatology Reports</i> , 0, , .	4.7	3
25	Addition of antifibrotic therapy to immunosuppression in hypersensitivity pneumonitis: A case series. <i>Respiratory Medicine Case Reports</i> , 2021, 34, 101562.	0.4	2
26	Pulmonary fibrosis screening: quantifying the psychological impact. <i>Thorax</i> , 2021, 76, 532-533.	5.6	0